Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
Hosted on MSN3d
Challenges remain in treating T2-low asthmaCurrent treatments focus on eosinophilic asthma, neglecting non-eosinophilic types. Developments in biologic therapies for ...
The association between early childhood serum 25-hydroxyvitamin D (25(OH)D) and eosinophilic asthma remains unclear. We ...
Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results ...
News Medical on MSN3d
Researchers uncover diverse asthma endotypes in youths using nasal transcriptomicsThe study highlights T2-low and T17-high asthma endotypes in minoritized youths, offering insights for precision medicine and ...
A recent novel study published in the New England Journal of Medicine found that Depemokimab can reduce asthma exacerbations ...
China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...
T2-Low Asthma: A Diagnostic and Therapeutic Challenge T2-low asthma presents unique challenges due to the absence of ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback